These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 21216588)

  • 1. Expression of DNA repair genes in ovarian cancer samples: biological and clinical considerations.
    Ganzinelli M; Mariani P; Cattaneo D; Fossati R; Fruscio R; Corso S; Ricci F; Broggini M; Damia G
    Eur J Cancer; 2011 May; 47(7):1086-94. PubMed ID: 21216588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.
    Darcy KM; Tian C; Reed E
    Cancer Res; 2007 May; 67(9):4474-81. PubMed ID: 17483363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.
    Fleming ND; Agadjanian H; Nassanian H; Miller CW; Orsulic S; Karlan BY; Walsh CS
    Cancer; 2012 Feb; 118(3):689-97. PubMed ID: 21751198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
    Smith S; Su D; Rigault de la Longrais IA; Schwartz P; Puopolo M; Rutherford TJ; Mor G; Yu H; Katsaros D
    J Clin Oncol; 2007 Nov; 25(33):5172-9. PubMed ID: 18024864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer.
    Weberpals J; Garbuio K; O'Brien A; Clark-Knowles K; Doucette S; Antoniouk O; Goss G; Dimitroulakos J
    Int J Cancer; 2009 Feb; 124(4):806-15. PubMed ID: 19035454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression.
    Bartolucci R; Wei J; Sanchez JJ; Perez-Roca L; Chaib I; Puma F; Farabi R; Mendez P; Roila F; Okamoto T; Taron M; Rosell R
    Clin Lung Cancer; 2009 Jan; 10(1):47-52. PubMed ID: 19289372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
    Qian XP; Liu BR; Shi MQ; Liu XZ; Hu WJ; Zou ZY; Wei J
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):33-7. PubMed ID: 19538866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer.
    Codegoni AM; Broggini M; Pitelli MR; Pantarotto M; Torri V; Mangioni C; D'Incalci M
    Gynecol Oncol; 1997 Apr; 65(1):130-7. PubMed ID: 9103402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.
    Dabholkar M; Vionnet J; Bostick-Bruton F; Yu JJ; Reed E
    J Clin Invest; 1994 Aug; 94(2):703-8. PubMed ID: 8040325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.
    Wang C; Horiuchi A; Imai T; Ohira S; Itoh K; Nikaido T; Katsuyama Y; Konishi I
    J Pathol; 2004 Feb; 202(2):215-23. PubMed ID: 14743504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer.
    Reed E; Yu JJ; Davies A; Gannon J; Armentrout SL
    Clin Cancer Res; 2003 Nov; 9(14):5299-305. PubMed ID: 14614013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
    Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
    Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
    Tan DS; Rothermundt C; Thomas K; Bancroft E; Eeles R; Shanley S; Ardern-Jones A; Norman A; Kaye SB; Gore ME
    J Clin Oncol; 2008 Dec; 26(34):5530-6. PubMed ID: 18955455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer].
    Liu GY; Qu QX; Mi RR; Qi J
    Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):184-7. PubMed ID: 18756932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy.
    Kamikozuru H; Kuramochi H; Hayashi K; Nakajima G; Yamamoto M
    Int J Oncol; 2008 May; 32(5):1091-6. PubMed ID: 18425336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of DNA repair gene expression in human cancer cell lines.
    McGurk CJ; Cummings M; Köberle B; Hartley JA; Oliver RT; Masters JR
    J Cell Biochem; 2006 Apr; 97(5):1121-36. PubMed ID: 16315315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma.
    Italiano A; Laurand A; Laroche A; Casali P; Sanfilippo R; Le Cesne A; Judson I; Blay JY; Ray-Coquard I; Bui B; Coindre JM; Nieto A; Tercero JC; Jimeno J; Robert J; Pourquier P
    Cancer; 2011 Aug; 117(15):3445-56. PubMed ID: 21287534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum.
    Deloia JA; Bhagwat NR; Darcy KM; Strange M; Tian C; Nuttall K; Krivak TC; Niedernhofer LJ
    Gynecol Oncol; 2012 Sep; 126(3):448-54. PubMed ID: 22609620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Zhou W; Gurubhagavatula S; Liu G; Park S; Neuberg DS; Wain JC; Lynch TJ; Su L; Christiani DC
    Clin Cancer Res; 2004 Aug; 10(15):4939-43. PubMed ID: 15297394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.